Citation Impact
Citing Papers
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
2012
Bacteremia Associated With Toothbrushing and Dental Extraction
2008 Standout
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
2010
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2008 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
2012
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Evolution of the Cancer Stem Cell Model
2014 Standout
An Overview of Cyclophosphamide and Ifosfamide Pharmacology
1997
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma
2016
Recent advances in the management of AL Amyloidosis
2015
Multiple myeloma
2014
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
2013
EGFR Antagonists in Cancer Treatment
2008 Standout
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
2005
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
2009
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
Proteasome inhibitors in cancer therapy
2017
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial
2015
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
The Treatment of Multiple Myeloma
1994
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
2012
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006
2010
Primed marrow for autologous and allogeneic transplantation: A review comparing primed marrow to mobilized blood and steady-state marrow
2004
Amyloid diseases of the heart: current and future therapies
2012
Cellular pathophysiology of ischemic acute kidney injury
2011 Standout
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Angiogenesis and antiangiogenic therapy in hematologic malignancies
2006
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
2015
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Placental Blood as a Source of Hematopoietic Stem Cells for Transplantation into Unrelated Recipients
1996
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
2010
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
2013
Genetically programmed chiral organoborane synthesis
2017 StandoutNatureNobel
Targeting cancer with small molecule kinase inhibitors
2008 Standout
A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells
2014 StandoutNobel
Fibroblast growth factor signalling: from development to cancer
2010 Standout
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
1997
Ba/F3 cells and their use in kinase drug discovery
2006
Outcomes among 562 Recipients of Placental-Blood Transplants from Unrelated Donors
1998 Standout
Cardiac amyloidosis: an approach to diagnosis and management
2010
Graft-versus-host disease
2009 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Antifungal prophylaxis for severely neutropenic chemotherapy recipients
2002
Genetic events in the pathogenesis of multiple myeloma
2007
Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma
2006
Systemic amyloidosis
2015 Standout
One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome.
1993
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
2006
Hindlimb Suspension and SPE-Like Radiation Impairs Clearance of Bacterial Infections
2014 StandoutNobel
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
Treatment of Relapsed/Refractory Multiple Myeloma
2009
Pathogenesis and treatment of renal failure in multiple myeloma
2008
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
2014
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
2012
CASK Functions as a Mg2+-Independent Neurexin Kinase
2008 StandoutNobel
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients
1993
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
2012
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
TRPA1 Mediates the Inflammatory Actions of Environmental Irritants and Proalgesic Agents
2006 StandoutNobel
The changing epidemiology of acute renal failure
2006
Metastatic colonization by circulating tumour cells
2016 StandoutNature
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
2008
Light chain deposition disease: novel biological insights and treatment advances
2012
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Tumor Angiogenesis
2008 Standout
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
2009
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
1994
An Analysis of Bacteremias During Dental Extractions
1996
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
2009
Boron Chemicals in Diagnosis and Therapeutics
2013
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
2013
Human mesenchymal stem cells modulate allogeneic immune cell responses
2004 Standout
Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program
1994
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
2012
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
2011
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
2010
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
2009
Current Trends in Diagnosis and Management of Cardiac Amyloidosis
2013
Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma
1995
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma
1993
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Unrelated donor marrow transplantation in children
1995
ANTIBIOTIC CONSIDERATIONS IN MEDICALLY COMPROMISED PATIENTS
1994
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline
2013
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
2014
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
2013
Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure?
2000
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
2006
How I treat multiple myeloma in younger patients
2009
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
2007
Systemic amyloidosis: novel therapies and role of biomarkers
2016
Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
1993
Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis
2007
Emerging Targets in Photopharmacology
2016 StandoutNobel
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Multiple Myeloma
2011 Standout
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor
2007
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
2009
A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
2008
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
2012
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
2000
Works of Donna Reece being referenced
Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
2008
Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
1991
Allogeneic marrow transplantation for refractory Hodgkin's disease.
1989
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
2012
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
2004
A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145
2006
Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.
1991
Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation
1992
Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants
1996
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
2011
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
2009
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
2013
Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
1991
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
2008
Multiple myeloma patients with CKS1B gene amplification have a shorter progression‐free survival post‐autologous stem cell transplantation
2006
High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation for Patients With Primary Systemic Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
2006
Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation
2005
Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation.
1991
Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome
2003
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma
2006
Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry
1999
Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.
2006
Use of Echocardiography in the Diagnosis of Cardiac AL Amyloidosis - An Analysis of "Presumed" and "Endomyocardial Biopsy-Proven" Disease.
2005
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
2009
G-CSF Primed Autologous Marrow Harvest and Transplantation in Cytapheresis “Mobilization Failure” Patients: A Descriptive Analysis
2000
Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.
2006
Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.
1991
Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023
2015
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
2004
Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance
2005
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
2011
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
2009
Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.
2007
Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.
2004
Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
2008
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
2004
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
2009
Light Chain Deposition Disease: Impact of Stem Cell Tranplant on Hematological Response Achievement.
2010
The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan
2007
Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial
2011
Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity
1991
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
2014
Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
1993